Vanguard Capital Management
TBPH icon

Vanguard Capital Management’s Theravance Biopharma TBPH Stock Holding History

Vanguard Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.1M Sell
1,771,493
-12,260
-0.7% -$203K ﹤0.01% 2216
2026
Q1 		$29M Buy
+1,783,753
New +$31.6M ﹤0.01% 2149

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's TBPH Position: Q2 2026 in Review

Vanguard Capital Management reduced its Theravance Biopharma (TBPH) stake by 0.69% in Q2 2026, selling an estimated $203K and leaving 1,771,493 shares worth $30.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2216.

Vanguard Capital Management first reported a position in TBPH in Q1 2026 and has held it in 2 quarters since. 178 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Vanguard Capital Management held 1,771,493 shares of Theravance Biopharma worth $30.1M as of Q2 2026.
  • Vanguard Capital Management sold 12,260 Theravance Biopharma shares in Q2 2026, an estimated $203K.
  • Theravance Biopharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2216 holding.
  • Vanguard Capital Management first reported a position in Theravance Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 178 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.